Market closed

Axsome Therapeutics/$AXSM

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Axsome Therapeutics

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Ticker

$AXSM
Trading on

Industry

Pharmaceuticals

Employees

607

AXSM Metrics

BasicAdvanced
$4.7B
Market cap
-
P/E ratio
-$6.53
EPS
1.25
Beta
-
Dividend rate
$4.7B
1.25
$99.50
$64.11
532K
2.442
2.301
203.872
207.001
-48.58%
-26.44%
-171.61%
13.75
50.96
146.32
-35.04
51.47%
43.92%
24.97%

What the Analysts think about AXSM

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.

AXSM Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AXSM Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AXSM

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Axsome Therapeutics stock?

Axsome Therapeutics (AXSM) has a market cap of $4.7B as of December 13, 2024.

What is the P/E ratio for Axsome Therapeutics stock?

The price to earnings (P/E) ratio for Axsome Therapeutics (AXSM) stock is 0 as of December 13, 2024.

Does Axsome Therapeutics stock pay dividends?

No, Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders as of December 13, 2024.

When is the next Axsome Therapeutics dividend payment date?

Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders.

What is the beta indicator for Axsome Therapeutics?

Axsome Therapeutics (AXSM) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.